Project Grant R01CA312279
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $577K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $752,280 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to decode basal cell multipotency as a precursor and therapeutic target in histological transformation across lung cancer subtypes. The award funds research into the molecular and cellular mechanisms driving adenocarcinoma transformation to small cell lung cancer or squamous cell carcinoma histology as a resistance mechanism...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $752,808 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate clonal hematopoiesis as a mechanism of therapeutic resistance in anaplastic thyroid cancer. The research examines how clonal hematopoiesis—the age-related expansion of mutant hematopoietic stem and progenitor cells—drives resistance to BRAF-MEK inhibitor therapy in anaplastic thyroid cancer patients. The project...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $444,590 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms. The research builds on a prior Phase I/II study (MPD-RC 109) testing combination therapy with the JAK1/2 inhibitor ruxolitinib and the hypomethylating agent decitabine in advanced MPN...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute, National Institutes of Health, awarded Sloan-Kettering Institute For Cancer Research $715,002 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop HER2 positron emission tomography imaging methods for assessing HER2 heterogeneity and predicting response to HER2-targeted therapies in biliary tract cancer. The project addresses treatment resistance in metastatic biliary tract cancer by using molecular imaging to...
- The National Institutes of Health National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $690,977 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to improve precision medicine for renal cell carcinoma patients of African ancestry through computational and functional genomics. The award funds research to identify novel molecular biomarkers and refine RCC classification in patients of African ancestry, where papillary RCC occurs more...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...